SI1587542T1 - Uporaba anti-cd100 protiteles - Google Patents

Uporaba anti-cd100 protiteles

Info

Publication number: SI1587542T1
Authority: SI; Slovenia
Prior art keywords: antibodies
Prior art date: 2003-01-31

Application number

SI200431917T

Other languages

English (en)

Inventor

Marie-Francoise Belin

Pascale Giraudon

Laurence Boumsell

Armand Bensussan

Original Assignee

Inst Nat Sante Rech Med

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-01-31

Filing date

2004-02-02

Publication date

2012-10-30

2004-02-02 Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med

2012-10-30 Publication of SI1587542T1 publication Critical patent/SI1587542T1/sl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Molecular Biology (AREA)
Virology (AREA)
Genetics & Genomics (AREA)
Oncology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Communicable Diseases (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Transplantation (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)

SI200431917T 2003-01-31 2004-02-02 Uporaba anti-cd100 protiteles SI1587542T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP03290247A EP1442749A1 (en)	2003-01-31	2003-01-31	Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
EP04707230A EP1587542B1 (en)	2003-01-31	2004-02-02	Use of anti-cd100 antibodies
PCT/EP2004/001743 WO2004067034A1 (en)	2003-01-31	2004-02-02	Use of anti-cd100 antibodies

Publications (1)

Publication Number	Publication Date
SI1587542T1 true SI1587542T1 (sl)	2012-10-30

Family

ID=32605433

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI200431917T SI1587542T1 (sl)	2003-01-31	2004-02-02	Uporaba anti-cd100 protiteles

Country Status (11)

Country	Link
US (2)	US8067247B2 (sl)
EP (2)	EP1442749A1 (sl)
JP (1)	JP4768597B2 (sl)
BR (1)	BRPI0406689A (sl)
CA (1)	CA2514226C (sl)
CY (1)	CY1112953T1 (sl)
DK (1)	DK1587542T3 (sl)
ES (1)	ES2388735T3 (sl)
PT (1)	PT1587542E (sl)
SI (1)	SI1587542T1 (sl)
WO (1)	WO2004067034A1 (sl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6576754B2 (en) *	1995-11-09	2003-06-10	Dana-Farber Cancer Institute	CD100 antigen and uses therefor
EP1442749A1 (en) *	2003-01-31	2004-08-04	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
US7919594B2 (en) *	2007-02-14	2011-04-05	Vaccinex, Inc.	Human anti-CD100 antibodies
EP3320920A1 (en)	2009-05-08	2018-05-16	Vaccinex, Inc.	Anti-cd100 antibodies and methods for using the same
EP2487242A1 (en) *	2011-02-09	2012-08-15	Ruprecht-Karls-Universität Heidelberg	B-type plexin antagonists and uses thereof
DK2711023T3 (en)	2011-05-13	2017-10-16	Nat Univ Corp Tokyo Medical & Dental Univ	osteogenesis
PT2766093T (pt) *	2011-10-11	2018-05-18	Vaccinex Inc	Utilização de moléculas de ligação a semaforina-4d para modulação da permeabilidade da barreira hematoencefálica
US8790652B2 (en)	2011-12-06	2014-07-29	Vaccinex, Inc.	Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
US9090709B2 (en) *	2012-03-28	2015-07-28	Vaccinex, Inc.	Anti-SEMA4D antibodies and epitopes
US9708601B2 (en)	2012-04-26	2017-07-18	Vaccinex, Inc.	Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) *	2012-05-11	2019-12-03	Vaccinex, Inc.	Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
SG10201902380SA (en)	2013-06-25	2019-04-29	Vaccinex Inc	Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases
NZ630881A (en)	2013-10-10	2016-03-31	Vaccinex Inc	Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) *	2013-10-21	2016-03-31	Vaccinex Inc	Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
WO2016089126A1 (ko)	2014-12-03	2016-06-09	사회복지법인 삼성생명공익재단	뉴로필린 1(Neuropilin 1)에 대한 항체 및 이의 용도
IL262232B2 (en)	2016-04-22	2024-06-01	Vaccinex Inc	Integral membrane protein display on poxvirus extracellular enveloped virions
AU2017273170B2 (en)	2016-06-03	2020-08-27	Aimed Bio Inc.	Anti-NRP1 antibody screening method
EP3494131B1 (en)	2016-08-02	2024-09-18	Vaccinex, Inc.	Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells
AU2018237549B2 (en)	2017-03-20	2024-08-01	Vaccinex, Inc.	Treatment of cancer with a semaphorin-4D antibody in combination with an epigenetic modulating agent
WO2018204895A1 (en)	2017-05-05	2018-11-08	Vaccinex, Inc.	Human anti-semaphorin 4d antibody
EP3824907A4 (en)	2018-07-19	2022-05-04	The University of Tokyo	Agent for treatment or prevention of htlv-1-associated myelopathy (ham), and ham treatment method
CN113631230A (zh)	2019-03-28	2021-11-09	瓦西尼斯公司	用于癌症治疗的脑信号蛋白-4d拮抗剂
AU2020322474A1 (en)	2019-08-01	2022-03-10	Vaccinex,Inc.	Combined inhibition of semaphorin-4D and TGFβ and compositions therefor
EP4172205A1 (en)	2020-06-25	2023-05-03	Vaccinex, Inc.	Use of semaphorin-4d binding molecules for the treatment of rett syndrome
CA3231551A1 (en)	2021-09-27	2023-03-30	Maurice Zauderer	Predictive outcome profiling for use of an anti-semaphorin-4d binding molecule to treat neurodegenerative disorders
US20230331863A1 (en)	2022-02-13	2023-10-19	Vaccinex, Inc.	Combination therapy with semaphorin-4d blockade and htt-lowering agent for treatment of huntington's disease
CN117866091A (zh) *	2022-10-12	2024-04-12	三优生物医药(上海)有限公司	抗cd100抗体及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2686087A1 (fr) *	1992-01-13	1993-07-16	Inst Nat Sante Rech Med	Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
US5639856A (en)	1993-09-13	1997-06-17	The Regents Of The University Of California	Semaphorin gene family
US6576754B2 (en) *	1995-11-09	2003-06-10	Dana-Farber Cancer Institute	CD100 antigen and uses therefor
US6635742B1 (en) *	2000-01-25	2003-10-21	Nuvelo, Inc.	Antibodies specific for semaphorin-like polypeptides
EP1442749A1 (en) *	2003-01-31	2004-08-04	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system

2003
- 2003-01-31 EP EP03290247A patent/EP1442749A1/en not_active Withdrawn
2004
- 2004-02-02 JP JP2006501920A patent/JP4768597B2/ja not_active Expired - Fee Related
- 2004-02-02 WO PCT/EP2004/001743 patent/WO2004067034A1/en active Application Filing
- 2004-02-02 ES ES04707230T patent/ES2388735T3/es not_active Expired - Lifetime
- 2004-02-02 US US10/544,031 patent/US8067247B2/en not_active Expired - Fee Related
- 2004-02-02 PT PT04707230T patent/PT1587542E/pt unknown
- 2004-02-02 DK DK04707230.1T patent/DK1587542T3/da active
- 2004-02-02 SI SI200431917T patent/SI1587542T1/sl unknown
- 2004-02-02 CA CA2514226A patent/CA2514226C/en not_active Expired - Fee Related
- 2004-02-02 BR BR0406689-8A patent/BRPI0406689A/pt not_active Application Discontinuation
- 2004-02-02 EP EP04707230A patent/EP1587542B1/en not_active Expired - Lifetime
2011
- 2011-10-11 US US13/270,449 patent/US20120027758A1/en not_active Abandoned
2012
- 2012-08-07 CY CY20121100707T patent/CY1112953T1/el unknown

Also Published As

Publication number	Publication date
JP4768597B2 (ja)	2011-09-07
JP2006516594A (ja)	2006-07-06
ES2388735T3 (es)	2012-10-18
US8067247B2 (en)	2011-11-29
EP1587542A1 (en)	2005-10-26
CA2514226A1 (en)	2004-08-12
US20060233793A1 (en)	2006-10-19
BRPI0406689A (pt)	2005-12-20
CA2514226C (en)	2015-04-28
PT1587542E (pt)	2012-07-18
DK1587542T3 (da)	2012-07-30
EP1442749A1 (en)	2004-08-04
US20120027758A1 (en)	2012-02-02
EP1587542B1 (en)	2012-06-13
CY1112953T1 (el)	2016-04-13
WO2004067034A1 (en)	2004-08-12

Publication	Publication Date	Title
SI1587542T1 (sl)	2012-10-30	Uporaba anti-cd100 protiteles
IL175935A0 (en)	2006-10-05	Solid forms of anti-egfr antibodies
EP1616881A4 (en)	2008-08-27	ANTI-MPL ANTIBODIES
IL175608A0 (en)	2006-09-05	Antibodies
PT1599504E (pt)	2015-03-02	Anticorpo modificado
GB0325192D0 (en)	2003-12-03	Method of use
EP1494693A4 (en)	2006-08-02	SPECIFIC ANTIBODIES TO CRIPTO
IL175773A0 (en)	2006-09-05	Anti-igfr1 antibody therapeutic combinations
IL173273A0 (en)	2006-06-11	Modified human igf-1r antibodies
AU158373S (en)	2005-11-14	Set of containers
PL375405A1 (en)	2005-11-28	Antibodies
EP1745573A4 (en)	2010-05-26	PROCESS FOR PREPARING 2-DEOXY-BETA-L-NUCLEOSIDES
HK1155670A1 (en)	2012-05-25	Therapeutic use of anti-cs1 antibodies
GB2404736B (en)	2006-01-04	Determination of geophone coupling
IL172511A0 (en)	2006-04-10	Specific human antibodies
GB0306618D0 (en)	2003-04-30	Antibody
IL172510A0 (en)	2006-04-10	Antibodies and uses thereof
GB0226878D0 (en)	2002-12-24	Antibodies
PL377902A1 (pl)	2006-02-20	Nowe zastosowanie kompleksu fosfor-azot-metal
GB2399559B (en)	2006-07-26	Construction of container
HK1209139A1 (en)	2016-03-24	Modified antibody
GB0329711D0 (en)	2004-01-28	Antibodies
GB0317974D0 (en)	2003-09-03	Novel antibodies
TW573602U (en)	2004-01-21	Avstract of the disclosrte
TW553243U (en)	2003-09-11	Structure of clotheshanger